Effects of phosphodiesterase inhibitors on hypoxic pulmonary vasoconstriction.: Influence of K+ channels and nitric oxide

被引:8
作者
Goirand, F [1 ]
Bardou, M [1 ]
Dumas, JP [1 ]
Rochette, L [1 ]
Dumas, M [1 ]
机构
[1] Fac Med, Lab Physiopathol & Pharmacol Cardiovasc Expt, F-21079 Dijon, France
关键词
hypoxic pulmonary vasoconstriction; phosphodiesterase inhibitor; K+ channel; nitric oxide;
D O I
10.1016/S0014-2999(01)00900-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We studied the relaxant effects of the cyclic nucleotide phosphodiesterase inhibitors theophylline (non-selective), rolipram (type IV, 3',5'-cyclic monophosphate (cAMP)-specific) and zaprinast (type V, 3',5'-cyclic monophosphate (cGMP)-specific) on the hypoxic vasoconstriction in the isolated perfused rat lung and the involvement of K+ channels and nitric oxide (NO) in these effects. K+ channels were inhibited by glibenclamide, charybdotoxin, apamin and 4-aminopyridine and nitric oxide synthase by L-N-G-nitroarginine methyl ester (L-NAME). Hypoxic ventilation produced a significant pressure response. L-NAME and 4-aminopyridine increased this response. Rolipram, zaprinast and theophylline shared the ability to oppose the hypoxic pulmonary vasoconstriction. The order of potency was zaprinast > rolipram > theophylline. Glibenclamide partially inhibited the relaxant effects of rolipram and theophylline. Charybdotoxin inhibited the dilator response to rolipram. Apamin inhibited partially the vasodilation induced by rolipram and zaprinast. 4-Aminopyridine inhibited partially the relaxant effects of theophylline. L-NAME failed to block the effects of the three compounds. These data illustrate different pharmacological profiles according to the phosphodiesterase inhibitors and support the potential interest of selective inhibitors as relaxant agents in pulmonary vessels. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:141 / 148
页数:8
相关论文
共 45 条
[1]   Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia [J].
Archer, SL ;
Huang, JMC ;
Reeve, HL ;
Hampl, V ;
Tolarova, S ;
Michelakis, E ;
Weir, EK .
CIRCULATION RESEARCH, 1996, 78 (03) :431-442
[2]   Potassium channels modulate hypoxic pulmonary vasoconstriction [J].
Barman, SA .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1998, 275 (01) :L64-L70
[4]   CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS [J].
BEAVO, JA .
PHYSIOLOGICAL REVIEWS, 1995, 75 (04) :725-748
[5]   M-AND-B 22948, A CGMP PHOSPHODIESTERASE INHIBITOR, IS A PULMONARY VASODILATOR IN LAMBS [J].
BRANER, DAV ;
FINEMAN, JR ;
CHANG, R ;
SOIFER, SJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (01) :H252-H258
[6]   Nitrovasodilators relax mesenteric microvessels by cGMP-induced stimulation of Ca-activated K channels [J].
Carrier, GO ;
Fuchs, LC ;
Winecoff, AP ;
Giulumian, AD ;
White, RE .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1997, 273 (01) :H76-H84
[7]   Effects of pimobendan and its active metabolite, UD-CG 212 Cl, on Ca2+-activated K+ channels in vascular smooth-muscle cells [J].
Chen, CH ;
Nakaya, Y ;
Minami, K ;
Kubo, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (06) :739-743
[8]   Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats [J].
Cohen, AH ;
Hanson, K ;
Morris, K ;
Fouty, B ;
McMurtry, IF ;
Clarke, W ;
Rodman, DM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :172-179
[9]   Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats [J].
Crilley, TK ;
Wanstall, JC ;
Bonnet, PA .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1998, 25 (05) :355-360
[10]   Comparison of responses to siguazodan, rolipram, and zaprinast in the feline pulmonary vascular bed [J].
De Witt, BJ ;
Marrone, JR ;
Kadowitz, PJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (02) :233-238